First oral drug for advanced or metastatic bladder cancer.
Erdafitinib is first targeted therapy for FGFR3 or FGFR2 genetic alteration.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.